Search results for "C25"

showing 10 items of 566 documents

Targeting MYCN in Pediatric and Adult Cancers

2021

The deregulation of theMYCfamily of oncogenes, includingc-MYC,MYCNandMYCLoccurs in many types of cancers, and is frequently associated with a poor prognosis. The majority of functional studies have focused onc-MYCdue to its broad expression profile in human cancers. The existence of highly conserved functional domains betweenMYCNandc-MYCsuggests thatMYCNparticipates in similar activities.MYCencodes a basic helix-loop-helix-leucine zipper (bHLH-LZ) transcription factor (TF) whose central oncogenic role in many human cancers makes it a highly desirable therapeutic target. Historically, as a TF, MYC has been regarded as “undruggable”. Thus, recent efforts focus on investigating methods to indi…

Cancer ResearchCancercofactorReviewSynthetic lethalityMYCBiologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPediatric cancerlcsh:RC254-282pediatric cancerOncologyTranscription (biology)MYCNCancer researchmedicinecancerFunctional studiesSuper-enhancer (SE)Transcription factorPsychological repressionN-Mycneoplasmstranscription factorFrontiers in Oncology
researchProduct

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction

2006

Abstract Background Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide and a major cause of cancer-related mortality. HCC is highly resistant to currently available chemotherapeutic drugs. Defects in apoptosis signaling contribute to this resistance. Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 protein family which interferes with mitochondrial activation. In a previous study we have shown that Mcl-1 is highly expressed in tissues of human HCC. In this study, we manipulated expression of the Mcl-1 protein in HCC cells by RNA interference and analyzed its impact on apoptosis sensitivity of HCC cells in vitro. Methods RNA interference was per…

Cancer ResearchCarcinoma HepatocellularMyeloidCellAntineoplastic AgentsApoptosisBiologylcsh:RC254-282RNA interferenceCell Line Tumorhemic and lymphatic diseasesGeneticsmedicineHumansneoplasmsLiver Neoplasmslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasedigestive system diseasesIn vitroNeoplasm ProteinsGene Expression Regulation NeoplasticLeukemiamedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2OncologyApoptosisHepatocellular carcinomaCancer researchMyeloid Cell Leukemia Sequence 1 ProteinRNA InterferenceStem cellResearch ArticleBMC Cancer
researchProduct

Erratum: Melanoma Unknown Primary Brain Metastasis Treatment With ECHO-7 Oncolytic Virus Rigvir: A Case Report

2018

Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of the disease. Melanoma brain metastases have many severe side effects and, unfortunately, any disease related to the brain has limited therapeutic options due to the blood–brain barrier. The course of the disease after a treatment course is complicated to predict, and it is difficult to obtain long-lasting remission. In this report, we describe a female patient with unknown primary melanoma brain metasta…

Cancer ResearchCase ReportBlood–brain barrierblood–brain barrierlcsh:RC254-282Text miningmelanoma brain metastasisRigvir®medicineECHO-7 virusoncolytic virusbusiness.industryMelanomaintranasalEcho (computing)medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virusmedicine.anatomical_structureOncologymelanoma unknown primaryCancer researchUnknown primaryErratumbusinessBrain metastasisFrontiers in Oncology
researchProduct

Cyclin dependent kinase-1 (Cdk-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (pdac)

2021

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans, due to late diagnosis and limited treatment possibilities. Improved treatment for PDAC patients is warranted. Cyclin-dependent kinase 1 (CDK1) is a stimulator of cell cycle progression and its activity is regularly enhanced in pancreatic cancer cells. Therefore, CDK1 has been proposed as a novel drug target to treat patients with PDAC. This review describes the potential of CDK1 inhibition as a treatment for PDAC by outlining the molecular pathways influenced by CDK1 inhibition and new therapeutic strategies. Abstract The role of CDK1 in PDAC onset and development is two-fold. Firstly, since …

Cancer ResearchCell cycle checkpointendocrine system diseasesmedicine.medical_treatmentReviewenvironment and public healthTargeted therapyCyclin-dependent kinaseCancer stem cellPancreatic cancermedicineNovel treatmentCDK1 inhibitionRC254-282Cyclin-dependent kinase 1biologyChemistryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPDACPancreatic cancerCell cyclemedicine.diseaseenzymes and coenzymes (carbohydrates)Oncologybiology.proteinCancer researchStem cellbiological phenomena cell phenomena and immunityCell cycle regulation
researchProduct

Socioeconomic Environment and Survival in Patients with Digestive Cancers: A French Population-Based Study

2021

Simple Summary Studies investigating the social gradient in digestive cancer survival are scarce, and the statistical methods used do not always consider important assumptions in survival analysis for adequate assessment. Using an ecological index (European Deprivation Index), we found a negative impact of social environment in digestive cancers net survival (especially for esophagus, stomach, bile ducts among females; colon and rectum for both sexes) and provided insight into how this social gradient in cancer survival builds up, and at what time of follow-up it appears. These results can guide clinical practice/public health actions to address social inequalities in survival by targeting …

Cancer ResearchColorectal cancerPopulationArticleBile duct cancerdeprivationmedicineFrench cancer registrieseducationSocioeconomic statusRC254-282education.field_of_studybusiness.industryBile ductStomachsocial gradientdigestive cancersNeoplasms. Tumors. Oncology. Including cancer and carcinogensSocial environmentCancermedicine.diseasemedicine.anatomical_structureOncologycancer net survivalbusinessdigestive cancers; cancer net survival; deprivation; social gradient; French cancer registriesDemographyCancers
researchProduct

Managing Multi-center Flow Cytometry Data for Immune Monitoring.

2014

With the recent results of promising cancer vaccines and immunotherapy 1 – 5 , immune monitoring has become increasingly relevant for measuring treatment-induced effects on T cells, and an essential tool for shedding light on the mechanisms responsible for a successful treatment. Flow cytometry is the canonical multi-parameter assay for the fine characterization of single cells in solution, and is ubiquitously used in pre-clinical tumor immunology and in cancer immunotherapy trials. Current state-of-the-art polychromatic flow cytometry involves multi-step, multi-reagent assays followed by sample acquisition on sophisticated instruments capable of capturing up to 20 parameters per cell at a…

Cancer ResearchComputer scienceData managementREST APIdata provenancecomputer.software_genrelcsh:RC254-282automated analysisData modelinglaboratory informatics03 medical and health sciences0302 clinical medicineLaboratory informaticsreproducible analysisFlow cytometry030304 developmental biologyOriginal Research0303 health sciencesApplication programming interfacebusiness.industrymetadatalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensData scienceAutomationMetadataManagement information systemsOncologyData miningdata managementbusinesscomputer030215 immunologyCommunication channelCancer informatics
researchProduct

Brain Mapping-Aided SupraTotal Resection (SpTR) of Brain Tumors: The Role of Brain Connectivity

2021

Brain gliomas require a deep knowledge of their effects on brain connectivity. Understanding the complex relationship between tumor and functional brain is the preliminary and fundamental step for the subsequent surgery. The extent of resection (EOR) is an independent variable of surgical effectiveness and it correlates with the overall survival. Until now, great efforts have been made to achieve gross total resection (GTR) as the standard of care of brain tumor patients. However, high and low-grade gliomas have an infiltrative behavior and peritumoral white matter is often infiltrated by tumoral cells. According to these evidences, many efforts have been made to push the boundary of the re…

Cancer ResearchConnectomicsmedicine.medical_specialtyMini Reviewlow-grade gliomasBrain tumorbrain connectomelcsh:RC254-282Brain mappingResectionLesionWhite matterNeuroimagingmedicineBrain connectome Supratotal resection Brain mapping Brain tumor Connectomics Extent of resection High-grade gliomas Low-grade GliomasconnectomicsBrain GliomaSettore MED/27 - Neurochirurgiabusiness.industryAstrocytomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseextent of resectionmedicine.anatomical_structureOncologySuprtotal resectionbrain mappingRadiologymedicine.symptomsupratotal resectionbusinesshigh-grade gliomasbrain tumorMRI
researchProduct

Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care

2021

Knowledge about genetic predisposition to pediatric cancer is constantly expanding. The categorization and clinical management of the best-known syndromes has been refined over the years. Meanwhile, new genes for pediatric cancer susceptibility are discovered every year. Our current work shares the results of genetically studying the germline of 170 pediatric patients diagnosed with cancer. Patients were prospectively recruited and studied using a custom panel, OncoNano V2. The well-categorized predisposing syndromes incidence was 9.4%. Likely pathogenic variants for predisposition to the patient’s tumor were identified in an additional 5.9% of cases. Additionally, a high number of pathogen…

Cancer ResearchCàncer en els infantsGenetic counselingBioinformaticsgermlineMedical careArticleDNA sequencingGermlineworking toolGenetic predispositionmedicinegenetic syndromeRC254-282genetic counselingbusiness.industryIncidence (epidemiology)Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancerpediatric oncologymedicine.diseasePediatric cancerOncologyhereditary cancerbusinessgenetic predispositionGenèticaCancers
researchProduct

R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair.

2010

Abstract Background CDK-inhibitors can diminish transcriptional levels of cell cycle-related cyclins through the inhibition of E2F family members and CDK7 and 9. Cyclin A1, an E2F-independent cyclin, is strongly upregulated under genotoxic conditions and functionally was shown to increase NHEJ activity. Cyclin A1 outcompetes with cyclin A2 for CDK2 binding, possibly redirecting its activity towards DNA repair. To see if we could therapeutically block this switch, we analyzed the effects of the CDK-inhibitor R-Roscovitine on the expression levels of cyclin A1 under genotoxic stress and observed subsequent DNA damage and repair mechanisms. Results We found that R-Roscovitine alone was unable …

Cancer ResearchDNA RepairDNA repairDNA damageSettore MED/06 - Oncologia MedicaCyclin DCyclin ACyclin BSettore BIO/11 - Biologia Molecolarelcsh:RC254-282RoscovitineProtein Kinase InhibitorsBIO/10 Biochimicaroscovitine doxorubicinbiologyResearchCyclin A1; Doxorubicin; Protein Kinase Inhibitors; Purines; Up-Regulation; DNA Damage; DNA Repair; Hydrogen-Ion Concentration; Cancer Research; Molecular Medicine; OncologyG2-M DNA damage checkpointHydrogen-Ion Concentrationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensUp-RegulationOncologyDoxorubicinPurinesCancer researchbiology.proteinMolecular MedicineCyclin A1biological phenomena cell phenomena and immunityCyclin A1Cyclin A2DNA DamageMolecular cancer
researchProduct

Aurora kinases in ovarian cancer

2020

Aurora kinases (AURK) are key regulators of the mitotic spindle formation. AURK is frequently overexpressed in ovarian cancer and this overexpression has been frequently associated with prognosis in these tumours. Interestingly, AURK have been shown to interact with DNA repair mechanisms and other cell cycle regulators. These functions have brought light to Aurora family as a potential target for anticancer therapy. In the last years, two clinical trials with different AURK inhibitors have shown activity in epithelial and clear-cell ovarian cancer. Although there is a lack of predictive factors of AURK inhibition activity, recent trials have identified some candidates. This review will focu…

Cancer ResearchDNA repairAurora inhibitorReviewCarcinoma Ovarian EpithelialProtein Serine-Threonine Kinaseslcsh:RC254-282aurora kinaseAurora kinaseAurora KinasesHumansMedicine1506Protein Kinase InhibitorsOvarian Neoplasmsbusiness.industryKinaseCell cyclemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSpindle apparatusClinical trialovarian cancerOncologyCancer researchFemalebusinessOvarian canceraurora inhibitorsESMO Open
researchProduct